Target type: biologicalprocess
Any process that decreases cell volume. [GOC:go_curators]
Negative regulation of cell volume is a critical cellular process that ensures the maintenance of proper cell size and shape. It involves a complex interplay of molecular mechanisms that respond to changes in osmotic pressure and maintain cellular homeostasis. Here's a detailed description of the biological process:
1. **Sensing Osmotic Changes:** Cells possess sophisticated mechanisms to detect changes in their surrounding osmotic environment. These include sensors located in the plasma membrane and cytoplasm that respond to variations in water potential. Key molecules involved in this sensing include:
* **Mechanosensitive ion channels:** These channels open or close in response to membrane tension, which is altered by changes in osmotic pressure. For example, stretch-activated channels allow the entry of ions, triggering signaling cascades.
* **Osmoreceptors:** These intracellular proteins detect changes in solute concentration and initiate downstream signaling pathways.
2. **Effector Mechanisms:** Once osmotic changes are sensed, cells activate a range of effector mechanisms to regulate their volume. These include:
* **Ion Transport:** Cells can actively transport ions across their membranes to adjust their internal solute concentration. Key players include:
* **Sodium-potassium pumps:** These pumps actively export sodium ions (Na+) and import potassium ions (K+), contributing to osmotic balance.
* **Aquaporins:** These water channels facilitate the rapid movement of water across cell membranes, responding to changes in osmotic pressure.
* **Other ion channels:** Specialized ion channels, like chloride channels, regulate the movement of specific ions, fine-tuning cell volume.
* **Organic Solute Accumulation:** Cells can also accumulate organic solutes, like amino acids and sugars, to counter osmotic stress. This process helps retain water within the cell, preventing excessive shrinkage.
* **Exocytosis and Endocytosis:** These processes involve the release or uptake of cellular materials, respectively. In response to osmotic changes, cells may release or internalize water and solutes to adjust their volume.
3. **Signaling Pathways:** The sensing and effector mechanisms are often connected by complex signaling pathways. These pathways involve:
* **Second messenger systems:** Molecules like cyclic AMP (cAMP) and calcium ions (Ca2+) are key mediators that relay osmotic signals.
* **Protein kinases and phosphatases:** These enzymes regulate the phosphorylation state of proteins, influencing their activity and contributing to volume regulation.
* **Transcription factors:** These proteins can alter gene expression, allowing cells to adjust the synthesis of proteins involved in volume regulation.
4. **Cellular Homeostasis:** Negative regulation of cell volume is a crucial process for maintaining cell function and survival. It ensures that cells:
* **Maintain their shape:** This is essential for cellular integrity and proper interactions with neighboring cells.
* **Maintain their internal environment:** Cell volume regulation is critical for optimal function of cellular organelles and processes.
* **Protect themselves from osmotic stress:** Changes in osmotic pressure can lead to cell swelling or shrinking, which can damage cellular structures and disrupt metabolism.
In summary, negative regulation of cell volume is a highly regulated and intricate process involving a complex interplay of sensors, effectors, and signaling pathways. It is essential for maintaining cellular homeostasis, protecting cells from osmotic stress, and ensuring proper cell function and survival.'
"
Protein | Definition | Taxonomy |
---|---|---|
P2X purinoceptor 7 | A P2X purinoceptor 7 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q99572] | Homo sapiens (human) |
Calcium-activated potassium channel subunit alpha-1 | A calcium-activated potassium channel subunit alpha-1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q12791] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
ns 1619 | NS 1619 : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which the hydrogens at positions 1 and 5 are replaced are replaced by 2-hydroxy-5-(trifluoromethyl)phenyl and trifluoromethyl groups, respectively. It is an opener/activator of the large-conductance calcium-activated potassium channel (Bkca). NS 1619: structure given in first source | (trifluoromethyl)benzenes; benzimidazoles; phenols | potassium channel opener |
oxatomide | oxatomide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one substituted by a 3-[4-(diphenylmethyl)piperazin-1-yl]propyl group at position 1. It is an anti-allergic drug. oxatomide: structure; an anti-allergic & an anti-asthmatic | benzimidazoles; diarylmethane; N-alkylpiperazine | anti-allergic agent; anti-inflammatory agent; geroprotector; H1-receptor antagonist; serotonergic antagonist |
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid | 5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid : An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6. pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid: a novel antagonist that selectively blocks P2 purinoceptor receptors; a useful tool to study co-transmission in tissues when ATP and coexisting neurotransmitters act in concert | arenesulfonic acid; azobenzenes; methylpyridines; monohydroxypyridine; organic phosphate; pyridinecarbaldehyde | purinergic receptor P2X antagonist |
suramin | suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years. Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties. | naphthalenesulfonic acid; phenylureas; secondary carboxamide | angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug |
alpha,beta-methyleneadenosine 5'-triphosphate | alpha,beta-methyleneadenosine 5'-triphosphate: do not confuse with beta,gamma-methylene ATP; RN given refers to parent cpd | nucleoside triphosphate analogue | |
sb 203580 | imidazoles; monofluorobenzenes; pyridines; sulfoxide | EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent | |
bms204352 | BMS204352: a calcium-sensitive opener of maxi-K potassium channels; structure in first source | ||
8-azidoadenosine 5'-triphosphate | |||
N-(5-chloro-2-hydroxyphenyl)-2-ethoxybenzamide | benzamides | ||
6-thioinosine-5'-triphosphate | organic molecule | ||
mrs2159 | MRS2159: an antagonist of both P2X1 and P2X7 receptors | ||
imd 0354 | N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first source | benzamides | |
kn 62 | KN 62: inhibitor of Ca/calmodulin-dependent protein kinase II | piperazines | |
az 11645373 | AZ 11645373: InChIKey: VQEHBLGYANQWEA-UHFFFAOYSA-N | ||
az10606120 | AZ10606120: a P2X7 receptor antagonist | ||
ce 224,535 | CE 224,535: structure in first source | ||
a-438079 | |||
af 353 | 5-(5-iodo-2-isopropyl-4-methoxyphenoxy)pyrimidine-2,4-diamine: a P2X3 and P2X2/3 receptor antagonist; structure in first source | ||
gsk1482160 | |||
a-839977 | A-839977: a selective P2X7 receptor antagonist, analgesic; structure in first source | ||
jnj-47965567 | JNJ-47965567: a P2X7 purinergic receptor antagonist; structure in first source | ||
mk-8742 | elbasvir : A complex organic heterotetracyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with grazoprevir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults. elbasvir: inhibits NS5A protein of hepatitis C virus | carbamate ester; imidazoles; L-valine derivative; N-acylpyrrolidine; organic heterotetracyclic compound; ring assembly | antiviral drug; hepatitis C virus nonstructural protein 5A inhibitor; hepatoprotective agent |